Mogrify Ltd
Generation of chondrocytes by cell conversion for regenerative medicine applications
- Funding £881,397
- Competition Improving Outcomes in Musculoskeletal Disorders
- Competition Date Autumn 2019
- Local AHSN Please Select
- Website https://mogrify.co.uk/
- Key Contact Dr. Karin Schmitt – Chief Business Officer
- Status In Development
-
Technology Biotechnology
Mogrify™ has developed a proprietary direct cellular conversion technology, which makes it possible to transform (transmogrify) any mature human cell type into any other without going through a pluripotent stem cell- or progenitor cell-state.
Mogrify is leveraging this technology to identify small molecules capable of converting expandable cell types into chondrocytes in order to create a scalable supply of allogeneic chondrocytes for use in regeneration of the joints in cartilage defects and osteoarthritis.
Comments are closed.